SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Income Taxes Payable
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Income Taxes Payable of -$2.54 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2020-11-06
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for the quarter ending 2020-09-30 was -$25.05M, a 1268.42% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for the quarter ending 2020-06-30 was $15.86M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for the quarter ending 2020-03-31 was $6.65M, a 37.03% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for the quarter ending 2019-12-31 was -$2.38M, a 162.03% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for fiscal 2019 was -$9.93M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for fiscal 2018 was -$3.56M, a 122.35% decline from fiscal 2017.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for fiscal 2017 was $15.93M, a 227485.71% increase from fiscal 2016.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in income taxes payable for fiscal 2016 was $7.00K.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|
| 2020-09-30 | -$25.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$9.19M derived: sum of 2 quarters · filed 2020-11-06 | -$2.54M 10-Q · filed 2020-11-06 | -$4.91M derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-06-30 | $15.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | $22.51M 10-Q · filed 2020-08-17 | $20.14M derived: sum of 3 quarters · filed 2020-08-17 | $22.28M derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-03-31 | $6.65M 10-Q · filed 2020-05-15 | $4.28M derived: sum of 2 quarters · filed 2020-05-15 | $6.42M derived: sum of 3 quarters · filed 2020-11-06 | -$8.14M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-12-31 | -$2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$231.00K derived: sum of 2 quarters · filed 2020-11-06 | -$14.79M derived: sum of 3 quarters · filed 2020-11-06 | -$9.93M 10-K · filed 2020-02-28 |
| 2019-09-30 | $2.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$12.41M derived: sum of 2 quarters · filed 2020-11-06 | -$7.56M 10-Q · filed 2020-11-06 | -$3.73M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | -$14.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | -$9.70M 10-Q · filed 2020-08-17 | -$5.87M derived: sum of 3 quarters · filed 2020-08-17 | $2.67M derived: sum of 4 quarters · filed 2020-08-17 |
| 2019-03-31 | $4.86M 10-Q · filed 2020-05-15 | $8.69M derived: sum of 2 quarters · filed 2020-05-15 | $17.23M derived: sum of 3 quarters · filed 2020-05-15 | $968.00K derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $12.38M derived: sum of 2 quarters · filed 2020-02-28 | -$3.89M derived: sum of 3 quarters · filed 2020-02-28 | -$3.56M 10-K · filed 2020-02-28 |
| 2018-09-30 | $8.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$7.72M derived: sum of 2 quarters · filed 2019-11-08 | -$7.39M 10-Q · filed 2019-11-08 | $2.06M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | -$16.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$15.94M 10-Q · filed 2019-08-09 | -$6.49M derived: sum of 3 quarters · filed 2020-02-28 | -$1.61M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $327.00K 10-Q · filed 2019-05-10 | $9.78M derived: sum of 2 quarters · filed 2020-02-28 | $14.66M derived: sum of 3 quarters · filed 2020-02-28 | $14.59M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $9.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $14.33M derived: sum of 2 quarters · filed 2020-02-28 | $14.26M derived: sum of 3 quarters · filed 2020-02-28 | $15.93M 10-K · filed 2020-02-28 |
| 2017-09-30 | $4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $4.81M derived: sum of 2 quarters · filed 2018-11-09 | $6.48M 10-Q · filed 2018-11-09 | $5.68M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.60M 10-Q · filed 2018-08-09 | $797.00K derived: sum of 3 quarters · filed 2019-03-01 | $1.58M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $1.67M 10-Q · filed 2018-05-10 | $864.00K derived: sum of 2 quarters · filed 2019-03-01 | $1.65M derived: sum of 3 quarters · filed 2019-03-01 | $1.65M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | -$804.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$22.00K derived: sum of 2 quarters · filed 2019-03-01 | -$15.00K derived: sum of 3 quarters · filed 2019-03-01 | $7.00K 10-K · filed 2019-03-01 |
| 2016-09-30 | $782.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $789.00K derived: sum of 2 quarters · filed 2017-11-09 | $811.00K 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $29.00K 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $22.00K 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |